Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Sponsor
Hoffmann-La Roche
Study ID
NCT01579006
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra in patients with rheumatoid arthritis who have had an inadequate response (or were intolerant to) treatment with non-biological DMARDs or with one biological agent. Data will be collected from each eligible patient initiated on RoActemra/Actemra treatment by their treating physician according to approved label for 6 months from start of treatment.

Key Dates

Start date
May 31, 2012
Status verified
Feb 2016
Primary completion
Mar 31, 2014
Completion
Mar 31, 2014

Study Design

Enrollment
184 participants (actual)

Arms

  • Arm: Cohort

Primary Outcome Measure

Percentage of Participants on TCZ Treatment at 6 Months After Treatment Initiation [ Time Frame: 6 months ]

Related Studies